Glenmark Pharma starts study on new cancer drug

Glenmark Pharmaceuticals on Friday announced discovery and initiation of enabling studies of an Investigational New Drug (IND) molecule targeted at cancer treatment.

The novel clinical development candidate, GBR1342, is an antibody based on the company's proprietary BEAT platform, Glenmark Pharmaceuticals said in a regulatory filing.

BEAT is Glenmark's technology for production of bi-specific antibodies.

ALSO READ: Glenmark gets tentative USFDA nod for generic Sanofi-Aventis' drug Multaq

GBR1342 is the second clinical development candidate following GBR1302 based on the BEAT technology. It is also Glenmark's second clinical candidate targeting oncology indications, it added.

Glenmark Pharmaceuticals Chief Scientific Officer and President, Biologics, Michael Buschle said, "With the 1302 project we learned how to efficiently engineer and manufacture this novel type of antibody and we are now applying those lessons to several other targets."